Home

EN / FR

Newsroom

03

Dec
2021

Uncategorized

Celyad Oncology Announces $32.5 Million Private Placement with Fortress Investment Group

Download PDF

12

Nov
2021

Uncategorized

Celyad Oncology Presents Preclinical Data on Allogeneic CAR T Therapy Program and Highlights KEYNOTE-B79 Clinical Trial Design at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

Download PDF

10

Nov
2021

Uncategorized

Celyad Oncology Announces Third Quarter 2021 Financial Results and Recent Business Highlights

Download PDF

04

Nov
2021

Uncategorized

Celyad Oncology to Present Updates from Allogeneic and Autologous CAR T Programs at 63rd ASH Annual Meeting and Exposition

Download PDF

02

Nov
2021

Uncategorized

Celyad Oncology Announces November 2021 Conference Schedule

Download PDF

29

Oct
2021

Uncategorized

Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Download PDF

01

Oct
2021

Uncategorized

Celyad Oncology to Present New Data on Allogeneic CAR T Therapy Program at the Society for Immunotherapy of Cancer Annual Meeting

Download PDF

01

Sep
2021

Uncategorized

Celyad Oncology announces September 2021 Conference Schedule

Download PDF

04

Aug
2021

Uncategorized

Celyad Oncology Reports First Half 2021 Financial Results and Recent Business Highlights

Download PDF

30

Jul
2021

Uncategorized

Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Download PDF

29

Jul
2021

Uncategorized

Celyad Oncology to Announce First Half 2021 Financial Results and Host Conference Call

Download PDF

20

Jul
2021

Press Releases, Uncategorized

Celyad Oncology Presents Updates on Allogeneic CAR T Clinical Candidates and shRNA-based Preclinical Concepts at Research & Development Day

Download PDF

13

Jul
2021

Uncategorized

Celyad Oncology to Host Virtual Research & Development Webinar on July 20th

Download PDF

07

Jul
2021

Press Releases, Uncategorized

Celyad Oncology to Participate at the William Blair Biotech Focus Conference 2021

Download PDF

30

Jun
2021

Inside Information, Uncategorized

Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Download PDF

11

Jun
2021

Uncategorized

Celyad Oncology Presents Preliminary Data from Phase 1 IMMUNICY-1 Trial of shRNA-based Allogeneic CAR T Candidate CYAD-211 in Relapsed/Refractory Multiple Myeloma at the European Hematology Association Virtual Congress

Download PDF

31

May
2021

Uncategorized

Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Download PDF

26

May
2021

Press Releases, Uncategorized

Celyad Oncology Announces June 2021 Conference Schedule

Download PDF

19

May
2021

Press Releases, Uncategorized

Transparency Notification received from Victory Capital Management Inc. (Article 14 §1 of the Law of 2 May 2007)

Download PDF

12

May
2021

Press Releases

Celyad Oncology to Present Data from Phase 1 IMMUNICY-1 Trial of Non-Gene Edited Allogeneic CAR T Candidate CYAD-211 in Relapsed/Refractory Multiple Myeloma at the European Hematology Association Virtual Congress

Download PDF

06

May
2021

Uncategorized

Celyad Oncology Announces First Quarter 2021 Financial Results and Recent Business Highlights

Download PDF

05

May
2021

Uncategorized

Transparency notification received from Tolefi SA (Article 14 §1 of the Law of 2 May 2007)

Download PDF

04

May
2021

Uncategorized

Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Download PDF

19

Apr
2021

Uncategorized

Celyad Oncology Appoints Dr. Charles Morris as Chief Medical Officer

Download PDF

01

Apr
2021

Uncategorized

Celyad Oncology Announces April 2021 Conference Schedule

Download PDF

31

Mar
2021

Uncategorized

Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Download PDF

24

Mar
2021

Uncategorized

Celyad Oncology Reports Full Year 2020 Financial Results and Recent Business Highlights

Download PDF

18

Mar
2021

Uncategorized

Celyad Oncology to Announce Full Year 2020 Financial Results and Host Conference Call

Download PDF

01

Mar
2021

Uncategorized

Celyad Oncology Announces March 2021 Conference Schedule

Download PDF

10

Feb
2021

Uncategorized

Letter to Shareholders – February 2021

Download PDF

02

Feb
2021

Uncategorized

Celyad Oncology Announces February 2021 Conference Schedule

Download PDF

18

Jan
2021

Uncategorized

Celyad Oncology Presents Data Update from Phase 1 alloSHRINK Trial for CYAD-101 in mCRC at ASCO-GI Symposium

Download PDF

11

Jan
2021

Uncategorized

Celyad Oncology Appoints Marina Udier, Ph.D., to Board of Directors

Download PDF

07

Jan
2021

Uncategorized

Celyad Oncology Announces Equity Purchase Agreement for up to $40 Million with Lincoln Park Capital

Download PDF

05

Jan
2021

Uncategorized

Celyad Oncology Announces January 2021 Conference Schedule

Download PDF

15

Dec
2020

Uncategorized

Celyad Oncology Successfully Doses First Patient in Expansion Cohort of the CYAD-101 Phase 1 alloSHRINK Trial for mCRC

Download PDF

07

Dec
2020

Uncategorized

Celyad Oncology Provides Updates on Allogeneic and Autologous CAR T Programs at 62nd ASH Annual Meeting and Exposition

Download PDF

04

Dec
2020

Uncategorized

Celyad Oncology Announces Dosing of First Patient in Phase 1 IMMUNICY-1 Trial of CYAD-211 for Multiple Myeloma

Download PDF

01

Dec
2020

Uncategorized

Celyad Oncology to Participate in a Fireside Chat at the JMP Securities Hematology Summit

Download PDF

10

Nov
2020

Uncategorized

Celyad Oncology Announces Third Quarter 2020 Financial Results and Recent Business Highlights

Download PDF

04

Nov
2020

Uncategorized

Celyad Oncology to Present Updates from Allogeneic and Autologous CAR T Programs at 62nd ASH Annual Meeting and Exposition

Download PDF

02

Nov
2020

Uncategorized

Celyad Oncology Announces November 2020 Investor Conference Schedule

Download PDF

29

Sep
2020

Uncategorized

Celyad Oncology Announces Clinical Trial Collaboration to Evaluate CYAD-101 with KEYTRUDA® (pembrolizumab) in Patients with Microsatellite Stable mCRC

Download PDF

23

Sep
2020

Uncategorized

Celyad Oncology to Participate in a Fireside Chat at the 7th Annual Jefferies Cell Therapy Summit

Download PDF

22

Sep
2020

Uncategorized

Celyad Oncology to Host Virtual Research & Development Webinar on September 29, 2020

14

Sep
2020

Uncategorized

Celyad Oncology Establishes At-the-Market Facility

Download PDF

26

Aug
2020

Uncategorized

Celyad Oncology Announces September 2020 Conference Schedule

Download PDF

06

Aug
2020

Uncategorized

Celyad Oncology Reports Half Year 2020 Financial Results and Second Quarter Business Highlights

Download PDF

03

Aug
2020

Uncategorized

Celyad Oncology to Announce First Half 2020 Financial Results and Host Conference Call

Download PDF

14

Jul
2020

Uncategorized

Celyad Oncology Announces FDA Clearance of IND Application for CYAD-211, First shRNA-based, Non-Gene Edited Allogeneic CAR T Therapy

Download PDF

10

Jun
2020

Uncategorized

Letter from the Chairman

Download PDF

10

Jun
2020

Uncategorized

Celyad Rebrands as Celyad Oncology

Download PDF

01

Jun
2020

Corporate, Non-regulated

Celyad Provides Update on Allogeneic CAR-T Franchise including CYAD-101 and shRNA Platform at the 2020 ASCO Virtual Scientific Program

Download PDF

26

May
2020

Corporate, Non-regulated

Celyad Announces June 2020 Conference Schedule

Download PDF

07

May
2020

Corporate, Regulated

Celyad Announces First Quarter 2020 Financial Results and Recent Business Highlights

Download PDF

06

May
2020

Corporate, Non-regulated

Celyad Appoints Seasoned Industry Executives to Board of Directors

Download PDF

30

Apr
2020

Corporate, Non-regulated

Celyad to Present Update from CYAD-101 for Advanced Colorectal Cancer and Next-Generation shRNA Platform at 2020 ASCO Virtual Scientific Program

Download PDF

22

Apr
2020

Corporate, Regulated

Celyad to Host Remote 2020 Ordinary General Meeting

Download PDF

24

Mar
2020

Corporate, Regulated

Celyad Reports Full Year 2019 Financial Results and Provides Business Update

Download PDF

12

Mar
2020

Corporate, Non-regulated

Celyad to Announce Full Year 2019 Financial Results and Host Conference Call

Download PDF

02

Mar
2020

Corporate, Non-regulated

Celyad Appoints Stephen Rubino as Chief Business Officer

Download PDF

17

Feb
2020

Corporate, Non-regulated

Celyad Announces February and March 2020 Conference Schedule

Download PDF

28

Jan
2020

Letter to Shareholders

Letter to Shareholders – January 2020

Download PDF

13

Jan
2020

Corporate, Non-regulated

Celyad Successfully Doses First Patient with CYAD-02 in CYCLE-1 Trial for r/r AML and MDS

Download PDF

10

Dec
2019

Corporate, Non-regulated

Celyad Presents Update on r/r AML and MDS Program at 61st ASH Annual Meeting

Download PDF

06

Dec
2019

Corporate, Regulated

Celyad Receives Additional €2.5 Million in Non-Dilutive Funding

Download PDF

29

Nov
2019

Corporate, Regulated

Celyad Announces Board of Directors Evolution with New Appointment

Download PDF

22

Nov
2019

Corporate, Non-regulated

Celyad Receives €8.5 Million in Grants and Non-Dilutive Funding by the Walloon Region

Download PDF

19

Nov
2019

Corporate, Regulated

Celyad Announces Third Quarter 2019 Financial Results and Recent Business Highlights

Download PDF

11

Nov
2019

Clinical, Immuno-oncology

Celyad Highlights Safety and Clinical Activity of CYAD-101, a First-In-Class, Non-Gene Edited Allogeneic CAR-T Therapy for mCRC, from SITC 34th Annual Meeting

Download PDF

06

Nov
2019

Clinical, Immuno-oncology

Celyad to Present Update to r/r AML and MDS Program at 2019 ASH Annual Meeting

Download PDF

05

Nov
2019

Clinical, Immuno-oncology

Celyad Highlights Abstracts from mCRC Clinical Program Released for SITC 34th Annual Meeting

Download PDF

02

Oct
2019

Clinical, Immuno-oncology

Celyad to Present Update on mCRC Clinical Program at the 2019 SITC Annual Meeting

Download PDF

02

Oct
2019

Corporate, Non-regulated

Celyad Announces October and November 2019 Investor Conference Schedule

Download PDF

16

Sep
2019

Corporate, Regulated

Celyad Announces Closing of $20 Million Global Offering

Download PDF

12

Sep
2019

Corporate, Regulated

Celyad Announces Pricing of $20.0 Million Global Offering

Download PDF

10

Sep
2019

Corporate, Regulated

Celyad Announces Launch of Proposed Global Offering

Download PDF

04

Sep
2019

Clinical, Immuno-oncology

Celyad Successfully Doses First Patient with CYAD-01 Produced with OptimAb Manufacturing Process

Download PDF

29

Aug
2019

Corporate, Non-regulated

Celyad to Participate in Upcoming September 2019 Conferences

Download PDF

22

Aug
2019

Corporate, Regulated

Celyad Reports Half Year 2019 Financial Results and Second Quarter Business Highlights

Download PDF

16

Aug
2019

Corporate, Non-regulated

Celyad to Provide First Half 2019 Financial Results & Business Highlights and Host a Conference Call

Download PDF

05

Jul
2019

Corporate, Non-regulated

Celyad Presents Update on Autologous & Allogeneic NKG2D-based CAR-T Therapies in Solid Tumors

Download PDF

02

Jul
2019

Corporate, Non-regulated

Celyad to Host Conference Call to Review Clinical Update from ESMO 21st World GI Congress

Download PDF

01

Jul
2019

Corporate, Non-regulated

Celyad Announces Strategic Updates to the Autologous r/r AML and MDS Program

Download PDF

17

Jun
2019

Clinical, Immuno-oncology

Celyad Presents Clinical Update for CYAD-01 at 24th Congress of the European Hematology Association

Download PDF

29

May
2019

Corporate, Non-regulated

Celyad to Participate in Upcoming June 2019 Conferences

Download PDF

16

May
2019

Corporate, Non-regulated

Celyad to Present Data at 24th Congress of the European Hematology Association

Download PDF

09

May
2019

Corporate, Regulated

Celyad Announces First Quarter 2019 Financial Results and Recent Business Highlights

Download PDF

02

May
2019

Corporate, Non-regulated

Celyad Announces May 2019 Investor Conference Schedule

Download PDF

17

Apr
2019

Clinical, Immuno-oncology

Celyad to Present Update on allogeneic and autologous NKG2D-based CAR-T Candidates in Refractory mCRC at ESMO 21st World GI Congress

Download PDF

01

Apr
2019

Corporate, Non-regulated

Celyad Announces April 2019 Investor Conference Schedule

Download PDF

28

Mar
2019

Corporate, Regulated

Celyad Appoints Filippo Petti as Chief Executive Officer

Download PDF

28

Mar
2019

Corporate, Regulated

Celyad Reports Business Update and Full Year 2018 Financial and Operating Results

Download PDF

22

Mar
2019

Corporate, Non-regulated

Celyad to Announce Full Year 2018 Financial Results and Host Conference Call

Download PDF

18

Mar
2019

Clinical, Immuno-oncology

Celyad’s 2019 R&D Day Highlights shRNA Platform and Pipeline of Next-generation NKG2D-based and Off-the-Shelf Non-gene Edited CAR-T Candidates

Download PDF

11

Mar
2019

Corporate, Non-regulated

Celyad to Host R&D Day and Webcast on Monday, March 18 in New York City

Download PDF

04

Mar
2019

Corporate, Non-regulated

Celyad Appoints Anne Moore as Vice President Corporate Strategy

Download PDF

21

Feb
2019

Corporate, Non-regulated

Celyad Announces February and March 2019 Investor Conference Schedule

Download PDF

07

Jan
2019

Financial Reports

Letter to Shareholders – January 2019

Download PDF

04

Dec
2018

Clinical

Celyad Presents Update on CYAD-01 Hematological Malignancies Clinical Program at 60th ASH Annual Meeting

Download PDF

30

Nov
2018

Clinical

Celyad Doses First mCRC Patient in the Phase 1 alloSHRINK Trial Evaluating Non-Gene Edited Allogeneic CAR-T Candidate, CYAD-101

Download PDF

21

Nov
2018

Corporate, Regulated

Celyad Announces Third Quarter 2018 Business Update

Download PDF

15

Nov
2018

Corporate, Non-regulated, Uncategorized

Celyad to Participate at Upcoming Healthcare Conferences

Download PDF

09

Nov
2018

Corporate, Regulated

Celyad Presents Update on CYAD-01 Solid Tumor Clinical Program at the SITC 33rd Annual Meeting

Download PDF

01

Nov
2018

Uncategorized

Celyad to Present New CYAD-01 Data from THINK Study in Relapsed/Refractory Acute Myeloid Leukemia at 2018 ASH Annual Meeting

Download PDF

04

Oct
2018

Corporate, Non-regulated

Celyad to present CYAD-01 solid tumor clinical updates and pre-clinical pipeline data at the 2018 SITC Annual Meeting

Download PDF

04

Oct
2018

Corporate, Regulated

Celyad Announces Exclusive Agreement for Horizon Discovery’s shRNA Platform to Develop Next-Generation Allogeneic CAR-T Therapies

Download PDF

28

Sep
2018

Corporate, Regulated

Transparency notification of Victory Capital Management Inc. (Article 14 of the Law of 2 May 2007)

Download PDF

26

Sep
2018

Corporate, Non-regulated

Celyad appoints Carri Duncan as Vice-President Corporate Development & Communications

Download PDF

25

Sep
2018

Corporate, Non-regulated

Celyad to Participate at Upcoming Healthcare Conferences

Download PDF

05

Sep
2018

Corporate, Non-regulated

Celyad Successfully Doses First Colorectal Cancer Patient with CYAD-01 Following Preconditioning Chemotherapy

Download PDF

30

Aug
2018

Corporate

Celyad to participate at upcoming healthcare conferences in September

Download PDF

23

Aug
2018

Uncategorized

Celyad Reports First Half 2018 Financial Results and Operational Progress

Download PDF

07

Aug
2018

Corporate, Regulated

Celyad Appoints Filippo Petti as Chief Financial Officer

Download PDF

01

Aug
2018

Corporate, Regulated

Dr. Margo Roberts joins Celyad’s Board of Directors and Scientific Committee

Download PDF

24

Jul
2018

Corporate, Immuno-oncology

Celyad Announces FDA Acceptance of IND Application for CYAD-101, a First-in-Class Non-Gene Edited Allogeneic CAR-T Candidate

Download PDF

18

Jul
2018

Corporate, Immuno-oncology

Information on the total number of voting rights and shares

Download PDF

19

Jun
2018

Corporate, Non-regulated

Celyad doses first AML patient at final dose level in CYAD-01 THINK trial and treats first patient with second cycle of therapy

Download PDF

23

May
2018

Corporate, Regulated

Celyad announces closing of global offering

Download PDF

17

May
2018

Corporate, Regulated

Celyad announces pricing of $47.3 million global offering

Download PDF

15

May
2018

Corporate, Regulated

Celyad Announces First Quarter 2018 Business Update

Download PDF

15

May
2018

Uncategorized

Celyad announces launch of proposed global offering

Download PDF

09

May
2018

Corporate, Non-regulated

Celyad Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2018

Download PDF

03

May
2018

Clinical, Immuno-oncology

Celyad successfully administers CYAD-01 in first patients in SHRINK and LINK trials

Download PDF

23

Apr
2018

Corporate, Non-regulated

Haematologica publishes Celyad THINK Study Case Report of CYAD-01 Induced Complete Remission in Relapsed/Refractory AML Patient

Download PDF

29

Mar
2018

Corporate, Non-regulated

Celyad to Present Updates on CYAD-01 at the American Association for Cancer Research (AACR) Annual Meeting 2018

Download PDF

22

Mar
2018

Corporate, Regulated

Celyad Reports 2017 Financial and Operating Results and Expected Key Milestones for 2018

Download PDF

13

Feb
2018

Corporate, Non-regulated

Celyad to Host Key Opinion Leader Meeting on CAR-T Therapy for the Treatment of Blood Cancers

Download PDF

01

Feb
2018

Corporate, Non-regulated

Celyad Provides Clinical Update and Strategic Outlook for 2018

Download PDF

22

Dec
2017

Corporate, Financial Reports

Letter to Shareholders – December 2017

Download PDF

21

Nov
2017

Corporate, Non-regulated

Celyad to Present at the 29th Annual Piper Jaffray Healthcare Conference

17

Nov
2017

Corporate, Regulated

Celyad Announces Third Quarter 2017 Business Update

Download PDF

07

Nov
2017

Clinical, Immuno-oncology

Celyad’s NKR-2 Phase I safety trial delivers encouraging results to be presented at ASH 2016

Download PDF

06

Oct
2017

Corporate, Non-regulated

Conference call – Update on Clinical Strategy

03

Oct
2017

Corporate, Regulated

Celyad reports a first complete response in a relapsed refractory AML patient in the THINK trial

Download PDF

21

Sep
2017

Corporate, Non-regulated

Celyad to Present at the Cantor Fitzgerald Global Healthcare Conference

Download PDF

30

Aug
2017

Corporate, Non-regulated

Conference call Celyad first half 2017

29

Aug
2017

Corporate, Regulated

Celyad Reports First Half 2017 Financial Results and Operational Progress

Download PDF

04

Aug
2017

Corporate, Regulated

Celyad announces new agreements with Celdara Medical and Dartmouth College

Download PDF

20

Jul
2017

Clinical, Immuno-oncology

Celyad announces initiation of the SHRINK trial

Download PDF

21

Jun
2017

Clinical, Immuno-oncology

Celyad publishes additional pre-clinical data in support of THINK trial

Download PDF

19

Jun
2017

Clinical, Immuno-oncology

Celyad reports promising early results at first dose level of the solid arm of the THINK trial

Download PDF

30

May
2017

Clinical, Immuno-oncology

Celyad obtains additional US patent for cancer treatment based on TCR-deficient allogeneic CAR-T cells

Download PDF

19

May
2017

Corporate, Regulated

Celyad Announces First Quarter 2017 Business Update

Download PDF

11

May
2017

Cardiology, Clinical

FDA grants Fast Track designation for Celyad’s ischemic heart failure therapy, C-Cure®

Download PDF

03

May
2017

Corporate, Non-regulated

Celyad to Present at the Deutsche Bank 42nd Annual Health Care Conference

Download PDF

02

May
2017

Corporate, Regulated

Celyad grants to Novartis a non-exclusive license for its allogeneic TCR-deficient CAR-T cells patents

Download PDF

28

Apr
2017

Clinical, Immuno-oncology

Celyad initiates second dose escalation in THINK trial in first US patient

Download PDF

27

Mar
2017

Clinical, Immuno-oncology

Celyad issues a White Paper about CAR T NKR-2 current knowledge and differences with classical CAR-T technologies

Download PDF

23

Mar
2017

Corporate, Regulated

Celyad Reports 2016 Financial and Operating Results and Expected Key Milestones for 2017

Download PDF

16

Mar
2017

Clinical, Immuno-oncology

USPTO rejects new reexamination request against Celyad’s US Patent for Production of Allogeneic TCR-Deficient CAR-T Cells

Download PDF

08

Mar
2017

Clinical, Immuno-oncology

Celyad obtains FDA approval to initiate the NKR-2 CAR T cells THINK trial in the USA

Download PDF

01

Mar
2017

Corporate, Non-regulated

Celyad to Present at Cowen and Company 37th Annual Health Care Conference

Download PDF

16

Feb
2017

Clinical, Immuno-oncology

Celyad Registers First Hematological Patient in CAR-T NKR-2 THINK Tri

Download PDF

13

Feb
2017

Corporate, Non-regulated

Christian Homsy talked about Celyad on Antipode radio!

06

Feb
2017

Corporate, Non-regulated

Celyad retains Piper Jaffray & Co. to explore strategic alternatives relating to its C-Cure® cardiovascular assets

Download PDF

11

Jan
2017

Clinical

Celyad Announces Registration of the First Pancreatic Cancer Patient in its CAR-T NKR-2 THINK Trial in Belgium

Download PDF

09

Jan
2017

Clinical, Immuno-oncology

Celyad Announces USPTO Decision to Uphold US Patent for Production of Allogeneic TCR-Deficient CAR-T Cells

Download PDF

05

Jan
2017

Clinical, Immuno-oncology

Celyad Announces Registration of the first patient in the Belgian THINK trial

Download PDF

06

Dec
2016

Clinical, Immuno-oncology

Celyad Announces Positive New Data from its CAR-T NKR-2 Phase I Trial at 2016 ASH Annual Meeting

Download PDF

21

Nov
2016

Clinical, Immuno-oncology

Celyad announces the approval to initiate its NKR-2 CAR-T Clinical Trial in Belgium

18

Nov
2016

Corporate, Regulated

Celyad announces third quarter 2016 business update

Download PDF

03

Nov
2016

Clinical, Immuno-oncology

Celyad responds to misleading statements on its patent relating to allogeneic human primary T-Cells that are engineered to be TCR-deficient and express a CAR

Download PDF

15

Sep
2016

Corporate, Non-regulated

Celyad CEO to present at the 2016 Cell & Gene Meeting on the Mesa

Download PDF

09

Sep
2016

Clinical, Immuno-oncology

Celyad completes the NKR-2 Phase I trial with successful safety follow-up of the fourth dose level

01

Sep
2016

Corporate, Non-regulated

Celyad appoints Philippe Dechamps as General Counsel and Company Secretary

Download PDF

28

Aug
2016

Corporate, Regulated

Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1): Clinical Trial Primary Outcomes

25

Aug
2016

Corporate, Regulated

Celyad Reports First Half 2016 Financial Results and Operational Progress

Download PDF

15

Jul
2016

Uncategorized

Celyad Letter to Shareholders

14

Jul
2016

Clinical, Immuno-oncology

Celyad successfully completes safety follow-up of the first patient at the fourth dose level in the NKR-2 Phase I trial

11

Jul
2016

Uncategorized

Celyad enters into license agreement with ONO PHARMACEUTICAL CO., LTD. to develop allogeneic NKR-2 T-cell immunotherapy

Download PDF

28

Jun
2016

Cardiology, Clinical

Celyad Announces Results for the CHART-1 Phase III Clinical Trial Evaluating C-Cure® Cell Therapy

Download PDF

23

Jun
2016

Uncategorized

Celyad treats first patient in the fourth dose level of its NKR-2 trial

Download PDF

14

Jun
2016

Corporate, Non-regulated

Celyad appoints Graham Morrell as Vice-President of Investors Relations & Communication

Download PDF

06

Jun
2016

Corporate, Non-regulated

Celyad appoints Dr. David Gilham as Vice-President of Research & Development

Download PDF

26

May
2016

Clinical, Immuno-oncology

Celyad successfully completes safety follow-up of the third dose level of its NKR-2 Trial

Download PDF

19

May
2016

Corporate, Regulated

Celyad announces first quarter 2016 business update

Download PDF

04

May
2016

Uncategorized

Celyad Announces Oral Presentation on NKR-2 T Cells Manufacturing for a First-in-Human Clinical Trial in AML and Multiple Myeloma

Download PDF

26

Apr
2016

Uncategorized

Celyad receives certification for C-Cure® non-clinical data from the European Medicines Agency (EMA)

Download PDF

14

Apr
2016

Corporate, Non-regulated

Celyad will present its NKR-2 immuno-oncology clinical program at 2016 ASCO Annual Meeting

Download PDF

06

Apr
2016

Uncategorized

Celyad appoints leading international Immuno-Oncology experts to Scientific Advisory Board

Download PDF

30

Mar
2016

Corporate

Letter to Shareholders – March 2016

Download PDF

30

Mar
2016

Clinical, Immuno-oncology

Celyad successfully completes safety follow-up of the first patient in the third dose level of its NKR-2 Trial

Download PDF

24

Mar
2016

Corporate, Regulated

Celyad reports 2015 Financial and Operating results

Download PDF

22

Mar
2016

Corporate, Non-regulated

Celyad announces collaboration with Institut Curie for the development of its immuno-oncology program NKR-T

Download PDF

18

Mar
2016

Cardiology, Clinical

Celyad notifies the European Medicines Agency (EMA) of its intention to file a Marketing Authorization Application (MAA) for C-Cure®

Download PDF

15

Mar
2016

Corporate, Non-regulated

Celyad to present at the Alliance for Regenerative Medicine’s 4th Annual Cell & Gene Therapy Investor Day

Download PDF

02

Mar
2016

Clinical, Immuno-oncology

Celyad receives the first US patent covering a method of producing Allogeneic TCR-deficient CAR T-cells

Download PDF

28

Feb
2016

Corporate, Non-regulated

Celyad to Host an Immuno-Oncology R&D Analyst Day on March 24th in New York City

Download PDF

26

Feb
2016

Corporate, Regulated

Cardio3 BioSciences to raise capital via a private placement of new shares

Download PDF

25

Feb
2016

Clinical, Immuno-oncology

Celyad successfully completes safety follow-up of the second dose level of patients in its NKR-2 Trial and enrolls first patient in the third dose level

Download PDF

08

Feb
2016

Corporate, Non-regulated

Prof. William Wijns appointed to chair the scientific committee that will oversee the CHART-1 data analysis and dissemination plan

Download PDF

03

Feb
2016

Cardiology, Clinical

Joint-PR-Invetech and Celyad SA Announce Collaboration to Realize the Commercial cGMP Production of C-Cure®

Download PDF

03

Feb
2016

Corporate, Non-regulated

Celyad appoints Dr. Richard Mountfield as Vice-President of Global Regulatory Affairs

Download PDF

20

Jan
2016

Corporate, Regulated

Celyad Announces 2016 Financial Calendar

Download PDF

05

Jan
2016

Clinical, Immuno-oncology

Celyad completes 30-day safety follow-up of first patient of second cohort in NKG2D CAR T-Cell Phase I Trial

Download PDF

04

Jan
2016

Corporate, Non-regulated

Celyad announces the appointment of Dr. Jean-Pierre Latere as Head of the Regenerative Medicine and Medical Device Franchise

Download PDF

23

Dec
2015

Corporate, Non-regulated

Celyad to address US institutional investors in January at J.P. Morgan Healthcare Conference

Download PDF

21

Dec
2015

Cardiology, Clinical

Celyad receives clearance from the US FDA on its CHART-2 Phase III IND

Download PDF

16

Dec
2015

Cardiology, Clinical

Celyad announces the publication of its CHART-1 trial design methods paper in the European Journal of Heart Failure

Download PDF

07

Dec
2015

Corporate, Non-regulated

Celyad announces the appointment of Pierre Brynaert as Chief Human Resources Officer

Download PDF

01

Dec
2015

Clinical, Immuno-oncology

Celyad treats first patient of second cohort in NKG2D CAR T-CELL Phase I Trial

Download PDF

25

Nov
2015

Corporate

Letter to Shareholders – November 2015

19

Nov
2015

Corporate, Regulated

Celyad announces third quarter 2015 business update

Download PDF

10

Nov
2015

Clinical, Immuno-oncology

Celyad successfully completes 30-day safety follow-up of first patient cohort in NKG2D CAR T-Cell Phase I Trial

Download PDF

06

Nov
2015

Corporate, Non-regulated

Celyad CEO Invited to Present at 2015 CAR-T Summit in Massachusetts.

Download PDF

05

Nov
2015

Cardiology, Clinical

Celyad initiates the certification by the EMA of the non-clinical data of C-Cure®

Download PDF

27

Oct
2015

Corporate, Non-regulated

List of key investors events Celyad will attend in the coming months

Download PDF

23

Oct
2015

Clinical, Immuno-oncology

First US Patent Covering Allogeneic Chimeric Antigen Receptor T Cells (“CAR-T”) Modified to Reduce Immunogenicity is Awarded to Celyad

Download PDF

13

Oct
2015

Corporate, Regulated

Advanced Therapies: forthcoming improvements to Belgium’s regulatory framework

Download PDF

05

Oct
2015

Corporate, Non-regulated

Celyad CEO Invited to Present at 2015 Stem Cell Me…Newsroom Celyad CEO Invited to Present at 2015 Stem Cell Meeting on the Mesa

Download PDF

29

Sep
2015

Corporate, Non-regulated

Celyad CMO to Chair the National Heart, Lung and Blood Institute Special Emphasis Panel

Download PDF

15

Sep
2015

Corporate, Non-regulated

Celyad announces the appointment of Dr. Frederic Lehmann as Vice President Immuno-Oncology

Download PDF

04

Sep
2015

Corporate, Non-regulated

Celyad announces the appointment of Dr. Debasish Roychowdhury as independent director

Download PDF

02

Sep
2015

Corporate, Non-regulated

Celyad participating in Large and Midcap Event in Paris

Download PDF

31

Aug
2015

Corporate, Non-regulated

Celyad announces commercial license agreement for C-Cure® in Greater China

Download PDF

25

Aug
2015

Corporate, Regulated

Celyad reports First Half 2015 financial results and operational progress

Download PDF

12

Aug
2015

Corporate, Regulated

HomeNewsCelyad Announces Details of Upcoming Half Year 201…Newsroom Celyad Announces Details of Upcoming Half Year 2015 Financial Results

Download PDF

03

Aug
2015

Cardiology, Clinical

Celyad completes final patient infusion in CHART-1 Phase III trial

Download PDF

24

Jun
2015

Corporate, Regulated

Celyad announces closing of its global offering

Download PDF

18

Jun
2015

Corporate, Regulated

Celyad raises $100.1 million gross proceeds with NASDAQ IPO

Download PDF

15

Jun
2015

Corporate, Regulated

Celyad announces launch of proposed global offering

Download PDF

11

Jun
2015

Clinical, Immuno-oncology

Celyad completes 30-day safety follow-up of first patient in NKG2D Phase I Trial

Download PDF

19

May
2015

Corporate, Regulated

Celyad announces first quarter 2015 business update

Download PDF

18

May
2015

Corporate, Regulated

Celyad announces filing of registration statement in the United States for a proposed global offering

Download PDF

05

May
2015

Corporate, Regulated

Cardio3 BioSciences Announces Results of Annual Shareholder Assembly 2015 and Confirmation of Name Change to Celyad

Download PDF

20

Apr
2015

Clinical, Immuno-oncology

Cardio3 BioSciences Announces Infusion of First Patient in NKG2D Phase I Trial

Download PDF

15

Apr
2015

Corporate, Non-regulated

Cardio3 BioSciences becomes Celyad

Download PDF

13

Apr
2015

Clinical, Immuno-oncology

Cardio3 BioSciences Enrolls First Patient in Phase I Trial for NKG2D CAR T-Cell

Download PDF

07

Apr
2015

Clinical, Immuno-oncology

Cardio3 BioSciences receives USPTO Notice of Allowance for first U.S. patent broadly covering TCR-deficient T-Cells engineered to express a chimeric antigen receptor

Download PDF

31

Mar
2015

Corporate, Regulated

Cardio3 BioSciences announces intention to conduct a registered public offering in the United States

Download PDF

30

Mar
2015

Cardiology, Clinical

Cardio3 BioSciences successfully completes futility analysis of lead cardiac cell therapy, C-Cure®

Download PDF

26

Mar
2015

Uncategorized

CArdio3 BioSciences Reports 2014 Financial and Operating Results

Download PDF

23

Mar
2015

Corporate, Non-regulated

Cardio3 BioSciences Announces Details of Upcoming Full-year 2014 Financial Results

Download PDF

22

Mar
2015

Corporate, Non-regulated

Cardio3 BioSciences to open new manufacturing facility in Rochester, MN to support CHART-2 Phase III Trial and U.S. growth

Download PDF

18

Mar
2015

Corporate, Non-regulated

Cardio3 BioSciences to Present at 3rd Annual Regen Med Investor Day

Download PDF

02

Mar
2015

Cardiology, Clinical

Cardio3 BioSciences marks first important milestone in regulatory path toward C-Cure® market registration with Paediatric Investigation Plan waiver from EMA

Download PDF

27

Feb
2015

Corporate, Regulated

Cardio3 BioSciences successfully completes a €32 Million private placement

Download PDF

26

Jan
2015

Corporate, Non-regulated

Cardio3 BioSciences Announces Agenda and webcast for 2015 NYC Investor Day

Download PDF

23

Jan
2015

Corporate, Non-regulated

Cardio3 BioSciences Announces its 2015 Financial Calendar

Download PDF

13

Jan
2015

Corporate, Regulated

Cardio3 BioSciences to host Investop & Analyst day in New York on Friday, January 30, 2015

Download PDF

08

Jan
2015

Corporate, Regulated

Cardio3 BioSciences appoints Vincent Brichard as vice-president Immuno-Oncology

Download PDF

06

Jan
2015

Corporate, Regulated

Cardio3 BioSciences enters immuno-oncology space with acquisition of oncyte car T-CELL portfolio from celdara medical

Download PDF

19

Dec
2014

Cardiology, Clinical

Cardio3 BioSciences announces the enrolment of the 240th patient for its CHART-1 phase III clinical trial for the treatment of heart failure

Download PDF

17

Dec
2014

Corporate, Non-regulated

Cardio3 BioSciences will be present at Oddo Midcap Forum

Download PDF

15

Dec
2014

Corporate, Non-regulated

Cardio3 BioSciences to address American institutional investors in January at J.P. Morgan Healthcare Conference

Download PDF

26

Nov
2014

Cardiology, Clinical

Cardio3 BioSciences announces the nomination of three Co-Principal Investigators for its CHART-2 phase III clinical trial of C-Cure® for the treatment of heart failure

Download PDF

18

Nov
2014

Corporate, Regulated

Cardio3 BioSciences announces Q3 2014 business update

Download PDF

05

Nov
2014

Corporate, Non-regulated

Cardio3 BioSciences acquires CorQuest Medical Inc.

Download PDF

23

Oct
2014

Corporate, Non-regulated

Cardio3 BioSciences appoints Dr. Warren Sherman as Chief Medical Officer

Download PDF

15

Oct
2014

Corporate, Non-regulated

Joint clarification regarding agreement between Cardio3 BioSciences and Mayo Clinic

Download PDF

13

Oct
2014

Cardiology, Clinical

Cardio3 BioSciences receives authorization to enroll patients in Switzerland in its Phase III Clinical trial Chart-1

Download PDF

08

Oct
2014

Corporate, Non-regulated

Cardio3 BioSciences awarded preferred access rights to all Mayo Clinic Center for Regenerative Medecine Portolio

Download PDF

01

Oct
2014

Corporate, Non-regulated

Cardio3 BioSciences announces new business development strategy to broaden its product pipeline

Download PDF

15

Sep
2014

Clinical, Immuno-oncology

Cardio3 BioSciences receives approval for the continuation of its chart-1 phase III clinical trial from the DSMB

Download PDF

22

Aug
2014

Corporate, Regulated

Cardio3 BioSciences reports 2014 half year financial results ans business update

Download PDF

09

Jul
2014

Corporate, Regulated

Cardio3 BioSciences Announces Secondary Placement …Newsroom Cardio3 BioSciences Announces Secondary Placement With New Institutional Investors

Download PDF

07

Jul
2014

Cardiology, Clinical

Cardio3 BioSciences to enroll the 120th patient for its CHART-1 study

Download PDF

01

Jul
2014

Corporate, Regulated

Cardio3 BioSciences Announces Completion of its Capital Increase of €25 Million at €44 per share.

Download PDF

16

Jun
2014

Corporate, Non-regulated

Cardio3 BioSciences teams up with Medisun International to create Cardio3 BioSciences Asia Holdings Ltd, a Joint Venture aimed at conducting pivotal clinical programs in Greater China

Download PDF

16

Jun
2014

Corporate, Regulated

Cardio3 BioSciences Announces a Capital Increase of €25 Million at €44 per share.

Download PDF

10

Jun
2014

Cardiology, Clinical

Cardio3 BioSciences Receives Authorization to Enroll Patients in Sweden in its Phase III Clinical Trial CHART-1

Download PDF

05

Jun
2014

Corporate, Non-regulated

Cardio3 BioSciences nominated for the European Mediscience Awards 2014

Download PDF

02

Jun
2014

Corporate, Non-regulated

Cardio3 BioSciences Appoints Dr. Georges Rawadi as VP Business Development

Download PDF

20

May
2014

Corporate, Regulated

Cardio3 BioSciences announces Q1 2014 business update ans confirms previous operational and financial guidance

Download PDF

19

May
2014

Corporate, Non-regulated

ardio3 BioSciences Signs First Sales Contract for C-Cathez ®

Download PDF

06

May
2014

Corporate, Non-regulated

EMA Grants Certification of Quality Data for C-Cure® to Cardio3 BioSciences

Download PDF

10

Apr
2014

Cardiology, Clinical

Cardio3 BioSciences Receives Authorization to Enroll Patients in Ireland in its Phase III Clinical Trial CHART-1

Download PDF

07

Apr
2014

Cardiology, Clinical

Cardio3 BioSciences’ Advanced Regenerative Technology Featured in European Heart Journal

Download PDF

31

Mar
2014

Corporate, Non-regulated

Cardio3 BioSciences Appoints Hanspeter Spek, Senior Pharmaceutical Executive to its Board of Directors

Download PDF

26

Mar
2014

Cardiology, Clinical

Cardio3 BioSciences’ cell therapy approach for cardiac repair recognized in Nature Reviews Cardiology

Download PDF

18

Mar
2014

Corporate, Regulated

Cardio3 BioScience Reports 2013 Financial results ans business update

Download PDF

24

Feb
2014

Corporate, Non-regulated

Cardio3 BioSciences Strengthens IP Portfolio with New US Patent

Download PDF

07

Feb
2014

Corporate, Non-regulated

Cardio3 BioSciences publishes its first Letter to Shareholders

Download PDF

09

Jan
2014

Cardiology, Clinical

Cardio3 BioSciences Receives IND Clearance from the FDA for its CHART-2 Phase III Heart Failure Clinical Trial

Download PDF

30

Dec
2013

Corporate, Non-regulated

Cardio3 BioSciences announces participation at the 32nd Annual JP Morgan Healthcare Conference in San Francisco

Download PDF

16

Dec
2013

Corporate, Regulated

Cardio3 BioSciences raises € 4.0 million in non-dilutive funding from the Walloon Region

Download PDF

11

Dec
2013

Corporate, Non-regulated

Cardio3 BioSciences C-Cath® Article Published in Circulation Cardiovascular Interventions

Download PDF

03

Dec
2013

Regulated

Cardio3 BioSciences Partner and Exploitation Manager of a Eur 6.8 Million FP7 Research Grant for AMCARE Program

Download PDF

25

Nov
2013

Corporate, Regulated

Cardio3 BioSciences Partner and Exploitation Manager of a Eur 4.5 Million FP7 Research Grant

Download PDF

21

Nov
2013

Corporate, Non-regulated

Cardio3 BioSciences Wins Trends-Tendances Business Tour Most Innovative Company Award 2013 for Wallonia

Download PDF

12

Nov
2013

Corporate, Regulated

Cardio3 Biosciences announces Q3 2013 business update and authorization to enroll patients in Poland in its chart-1 Phase III Clinical Trial

Download PDF

17

Oct
2013

Corporate, Non-regulated

Cardio3 BioSciences Wins Trends-Tendances Business Tour Most Innovative Company Award 2013 for Walloon Brabant

Download PDF

11

Oct
2013

Cardiology, Corporate

Cardio3 BioSciences to participate at the KBC Securities Benelux Biotech Healthcare Conference in New York on November 13 & 14

Download PDF

07

Oct
2013

Corporate, Non-regulated

Cardio3 BioSciences strengthens management team by appointing Dr. Gaëtane Metz as Chief Operating OfficerAuto Draft

Download PDF

03

Oct
2013

Cardiology, Clinical

Cardio3 BioSciences Receives Authorization to Enroll Patients in Italy in its Phase III Clinical Trial CHART-1

Download PDF

30

Sep
2013

Cardiology, Clinical

Cardio3 BioSciences Receives Authorization to Begin World’s First Phase III Clinical Trial in Regenerative Medicine for Heart Failure in Spain

Download PDF

28

Aug
2013

Corporate, Regulated

Cardio3 Biosciences announces half year financial results and business update

Download PDF

25

Jul
2013

Corporate, Regulated

Cardio3 BioSciences obtains the qualification of “Innovative Company” resulting in tax incentives for specific French investors

Download PDF

18

Jul
2013

Corporate, Regulated

Information on the total number of voting rights and shares

Download PDF

15

Jul
2013

Corporate, Regulated

Cardio3 BioSciences: Exercise of Over-allotment Option Total proceeds from the IPO €26.5m

Download PDF

12

Jul
2013

Corporate, Non-regulated

Transparency Notification Tolefi SA Participatie Maatschappij Vlaanderen NV, SRIW SA / SA SOFIPOLE and Mayo Foundation for Medical Research and Education

Download PDF

04

Jul
2013

Corporate, Regulated

Cardio3 BioSciences Raises EUR 23.0 million in Successful Initial Public Offering on NYSE Euronext Brussels and NYSE Euronext Paris

Download PDF

20

Jun
2013

Corporate, Regulated

Cardio3 BioSciences Launches its Initial Public Offering on NYSE Euronext Brussels and NYSE Euronext Paris

Download PDF

10

Jun
2013

Cardiology, Clinical

Cardio3 BioSciences Treats First Patients in World’s First Phase III Clinical Trial Using Pre-Programmed Cells for the Treatment of Heart Failure

Download PDF

04

Jun
2013

Corporate, Regulated

Cardio3 BioSciences Announces Intention to Launch an Initial Public Offering on NYSE Euronext Brussels and NYSE Euronext Paris

Download PDF

08

May
2013

Corporate, Regulated

Cardio3 BioSciences raises €19 million through a Private Placement

Download PDF

11

Apr
2013

Cardiology, Clinical

Results from Cardio3BioSciences C-CURE® Trial Published in the Journal of the American College of Cardiology

Download PDF

18

Nov
2012

Cardiology, Clinical

Cardio3 BioSciences Receives Authorization to Begin World’s First Phase III Clinical Trial in Regenerative Medicine for Heart Failure

18

May
2012

Corporate, Non-regulated

Cardio3 BioSciences Has Been Selected to Present C3BS-CQR-1 Trial Data in Late Breaking Clinical Trial Session at European Society of Cardiology 2012 Heart Failure Congress

09

May
2012

Corporate, Non-regulated

Cardio3 BioSciences Announces CE Marking for its C-Cath® Injection Catheter

12

Apr
2012

Corporate, Non-regulated

Cardio3 BioSciences Granted GMP Certification

28

Feb
2012

Corporate, Non-regulated

Cardio3 BioSciences Receives ISO-13485 Certification

02

Jan
2012

Corporate, Regulated

Cardio3 BioSciences Secures Additional €3.1 million in Non-dilutive Funding from the Walloon Region and the European Commission

22

Sep
2011

Corporate, Non-regulated

Cardio3 BioSciences Establishes US Subsidiary in Rochester, MN

29

Jun
2011

Corporate, Non-regulated

Cardio3 BioSciences and ATMI, Inc. Sign a Letter of Intent

16

May
2011

Cardiology, Clinical

Cardio3 BioSciences Presents C-Cure® Phase II Clinical Trial Results at the EuroPCR Meeting

05

Apr
2011

Cardiology, Clinical

Cardio3 BioSciences Announces International C-Cure® Phase II Clinical Trial at the 60th Annual American College of Cardiology Meeting

23

Feb
2011

Corporate, Non-regulated

Cardio3 BioSciences Appoints Drs Jan Andersson and Louise Proulx to its Board of Directors

.fl-heading-text